SciBase announces sale of Nevisense to NIH (US)

"The fact that this prestigious governmental institution has chosen to use Nevisense in their research speaks volumes about the credibility and reliability of our product," says Pia Renaudin, CEO of SciBase. "The skin barrier research market is experiencing a rapid rise in interest, and the research in this space can directly improve the lives of millions of people worldwide. We are confident that the use of our device by the NIH will lead to groundbreaking discoveries and advancements in the field of dermatology."

STOCKHOLM, 27/09/2024 (informazione.it - comunicati stampa - salute e benessere)

" " says Pia Renaudin , CEO of SciBase. " ."

Nevisense is, apart from being able to detect skin cancer, also designed to analyze skin barrier function with the highest accuracy and robustness available, making it an essential tool for researchers. To date, studies have included Nevisense to study skin disorders, investigate environmental irritants and their effect on skin health, and analyze skin barrier dysfunction as it relates to allergies.

For more information on Nevisense for research and SciBase's medical products, visit www.scibase.com  or contact Jeremy Bost at jeremy.bost@scibase.com  .

Pia Renaudin , CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail:  certifiedadviser@carnegie.se

 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-announces-sale-of-nevisense-to-nih--us-,c4043952

The following files are available for download:

View original content: https://www.prnewswire.co.uk/news-releases/scibase-announces-sale-of-nevisense-to-nih-us-302261013.html